Annexin A2 is a Natural Extrahepatic Inhibitor of the PCSK9-induced LDL Receptor Degradation

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2012 Aug 1

PMID 22848640

Citations 51

Authors

Nabil G Seidah

Steve Poirier

Maxime Denis

Rex Parker

Bowman Miao

Claudio Mapelli

Annik Prat

Hanny Wassef

Jean Davignon

Katherine A Hajjar

Gaetan Mayer

Affiliations

Soon will be listed here.

Abstract

Proprotein convertase subtilisin/kexin-9 (PCSK9) enhances the degradation of hepatic low-density lipoprotein receptor (LDLR). Deletion of PCSK9, and loss-of-function mutants in humans result in lower levels of circulating LDL-cholesterol and a strong protection against coronary heart disease. Accordingly, the quest for PCSK9 inhibitors has major clinical implications. We have previously identified annexin A2 (AnxA2) as an endogenous binding partner and functional inhibitor of PCSK9. Herein, we studied the relevance of AnxA2 in PCSK9 inhibition and lipid metabolism in vivo. Plasma analyses of AnxA2(-/-) mice revealed: i) a ∼1.4-fold increase in LDL-cholesterol without significant changes in VLDLs or HDLs, and ii) a ∼2-fold increase in circulating PCSK9 levels. Western blotting and immunohistochemistry of AnxA2(-/-) tissues revealed that the LDLR was decreased by ∼50% in extrahepatic tissues, such as adrenals and colon. We also show that AnxA2-derived synthetic peptides block the PCSK9≡LDLR interaction in vitro, and adenoviral overexpression of AnxA2 in mouse liver increases LDLR protein levels in vivo. These results suggest that AnxA2 acts as an endogenous regulator of LDLR degradation, mostly in extrahepatic tissues. Finally, we identified an AnxA2 coding polymorphism, V98L, that correlates with lower circulating levels of PCSK9 thereby extending our results on the physiological role of AnxA2 in humans.

Citing Articles

The Emerging Role of PCSK9 in the Pathogenesis of Alzheimer's Disease: A Possible Target for the Disease Treatment.

Testa G, Giannelli S, Staurenghi E, Cecci R, Floro L, Gamba P Int J Mol Sci. 2025; 25(24.

PMID: 39769398 PMC: 11727734. DOI: 10.3390/ijms252413637.

The multifaceted role of PCSK9 in cancer pathogenesis, tumor immunity, and immunotherapy.

Hsu C, Abdulrahim M, Mustafa M, Omar T, Balto F, Pineda I Med Oncol. 2024; 41(8):202.

PMID: 39008137 DOI: 10.1007/s12032-024-02435-0.

PCSK9 and Lipid Metabolism: Genetic Variants, Current Therapies, and Cardiovascular Outcomes.

Grejtakova D, Boronova I, Bernasovska J, Bellosta S Cardiovasc Drugs Ther. 2024; .

PMID: 38907775 DOI: 10.1007/s10557-024-07599-5.

Proteomics research of SARS-CoV-2 and COVID-19 disease.

Zhang N, Wang S, Wong C Med Rev (2021). 2023; 2(4):427-445.

PMID: 37724330 PMC: 10388787. DOI: 10.1515/mr-2022-0016.

Tale of two systems: the intertwining duality of fibrinolysis and lipoprotein metabolism.

Dai W, Castleberry M, Zheng Z J Thromb Haemost. 2023; 21(10):2679-2696.

PMID: 37579878 PMC: 10599797. DOI: 10.1016/j.jtha.2023.08.004.

References

Rousselet E, Marcinkiewicz J, Kriz J, Zhou A, Hatten M, Prat A . PCSK9 reduces the protein levels of the LDL receptor in mouse brain during development and after ischemic stroke. J Lipid Res. 2011; 52(7):1383-91. PMC: 3111744. DOI: 10.1194/jlr.M014118. View

Schmidt R, Beyer T, Bensch W, Qian Y, Lin A, Kowala M . Secreted proprotein convertase subtilisin/kexin type 9 reduces both hepatic and extrahepatic low-density lipoprotein receptors in vivo. Biochem Biophys Res Commun. 2008; 370(4):634-40. DOI: 10.1016/j.bbrc.2008.04.004. View

Shan L, Pang L, Zhang R, Murgolo N, Lan H, Hedrick J . PCSK9 binds to multiple receptors and can be functionally inhibited by an EGF-A peptide. Biochem Biophys Res Commun. 2008; 375(1):69-73. DOI: 10.1016/j.bbrc.2008.07.106. View

Gupta N, Fisker N, Asselin M, Lindholm M, Rosenbohm C, Orum H . A locked nucleic acid antisense oligonucleotide (LNA) silences PCSK9 and enhances LDLR expression in vitro and in vivo. PLoS One. 2010; 5(5):e10682. PMC: 2871785. DOI: 10.1371/journal.pone.0010682. View

Zhang D, Lagace T, Garuti R, Zhao Z, McDonald M, Horton J . Binding of proprotein convertase subtilisin/kexin type 9 to epidermal growth factor-like repeat A of low density lipoprotein receptor decreases receptor recycling and increases degradation. J Biol Chem. 2007; 282(25):18602-18612. DOI: 10.1074/jbc.M702027200. View

Mayer G, Boileau G, Bendayan M . The proprotein convertase furin colocalizes with caveolin-1 in the Golgi apparatus and endosomes of hepatocytes. Cell Tissue Res. 2004; 316(1):55-63. DOI: 10.1007/s00441-004-0866-x. View

Seidah N . PCSK9 as a therapeutic target of dyslipidemia. Expert Opin Ther Targets. 2008; 13(1):19-28. DOI: 10.1517/14728220802600715. View

Du F, Hui Y, Zhang M, Linton M, Fazio S, Fan D . Novel domain interaction regulates secretion of proprotein convertase subtilisin/kexin type 9 (PCSK9) protein. J Biol Chem. 2011; 286(50):43054-61. PMC: 3234880. DOI: 10.1074/jbc.M111.273474. View

Grefhorst A, McNutt M, Lagace T, Horton J . Plasma PCSK9 preferentially reduces liver LDL receptors in mice. J Lipid Res. 2008; 49(6):1303-11. PMC: 2386900. DOI: 10.1194/jlr.M800027-JLR200. View

10.

Zhao Z, Tuakli-Wosornu Y, Lagace T, Kinch L, Grishin N, Horton J . Molecular characterization of loss-of-function mutations in PCSK9 and identification of a compound heterozygote. Am J Hum Genet. 2006; 79(3):514-23. PMC: 1559532. DOI: 10.1086/507488. View

11.

Rashid S, Curtis D, Garuti R, Anderson N, Bashmakov Y, Ho Y . Decreased plasma cholesterol and hypersensitivity to statins in mice lacking Pcsk9. Proc Natl Acad Sci U S A. 2005; 102(15):5374-9. PMC: 556275. DOI: 10.1073/pnas.0501652102. View

12.

Genest J, McPherson R, Frohlich J, Anderson T, Campbell N, Carpentier A . 2009 Canadian Cardiovascular Society/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult - 2009 recommendations. Can J Cardiol. 2009; 25(10):567-79. PMC: 2782500. DOI: 10.1016/s0828-282x(09)70715-9. View

13.

Thompson J, Hyde C, Wood L, Paciga S, Hinds D, Cox D . Comprehensive whole-genome and candidate gene analysis for response to statin therapy in the Treating to New Targets (TNT) cohort. Circ Cardiovasc Genet. 2009; 2(2):173-81. DOI: 10.1161/CIRCGENETICS.108.818062. View

14.

Luo Y, Warren L, Xia D, Jensen H, Sand T, Petras S . Function and distribution of circulating human PCSK9 expressed extrahepatically in transgenic mice. J Lipid Res. 2008; 50(8):1581-8. PMC: 2724049. DOI: 10.1194/jlr.M800542-JLR200. View

15.

Cohen J, Pertsemlidis A, Kotowski I, Graham R, Garcia C, Hobbs H . Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9. Nat Genet. 2005; 37(2):161-5. DOI: 10.1038/ng1509. View

16.

Poirier S, Mayer G, Poupon V, McPherson P, Desjardins R, Ly K . Dissection of the endogenous cellular pathways of PCSK9-induced low density lipoprotein receptor degradation: evidence for an intracellular route. J Biol Chem. 2009; 284(42):28856-64. PMC: 2781431. DOI: 10.1074/jbc.M109.037085. View

17.

Zaid A, Roubtsova A, Essalmani R, Marcinkiewicz J, Chamberland A, Hamelin J . Proprotein convertase subtilisin/kexin type 9 (PCSK9): hepatocyte-specific low-density lipoprotein receptor degradation and critical role in mouse liver regeneration. Hepatology. 2008; 48(2):646-54. DOI: 10.1002/hep.22354. View

18.

Dubuc G, Chamberland A, Wassef H, Davignon J, Seidah N, Bernier L . Statins upregulate PCSK9, the gene encoding the proprotein convertase neural apoptosis-regulated convertase-1 implicated in familial hypercholesterolemia. Arterioscler Thromb Vasc Biol. 2004; 24(8):1454-9. DOI: 10.1161/01.ATV.0000134621.14315.43. View

19.

Kraemer F . Adrenal cholesterol utilization. Mol Cell Endocrinol. 2007; 265-266:42-5. DOI: 10.1016/j.mce.2006.12.001. View

20.

Saris C, Kristensen T, DEustachio P, Hicks L, Noonan D, Hunter T . cDNA sequence and tissue distribution of the mRNA for bovine and murine p11, the S100-related light chain of the protein-tyrosine kinase substrate p36 (calpactin I). J Biol Chem. 1987; 262(22):10663-71. View